Kinara Vision Technologies
First-in-class microstent restoring physiological outflow for an underserved patient group.
Investigational device — not approved for clinical use.
Supported by
The Challenge
Angle-closure glaucoma is more aggressive than open-angle disease, carries a higher risk of blindness, and disproportionately affects Asian populations — yet has no long-term solution that is both safe and effective.
Introducing Flostream
Flostream is a microstent that creates an alternative outflow pathway, bypassing the trabecular meshwork and closed angle entirely. It is placed with a single-use deployment system designed for accurate, repeatable delivery.
Why It Matters
Creates access to drainage independent of closed angle, bypassing the obstruction entirely.
Designed for controlled intraocular pressure management with sustained outcomes.
Targets an underserved patient population with limited minimally invasive options today.
Who We are Building For
Angle-closure glaucoma affects over 30 million people in Asia, causing irreversible blindness at twice the rate of open-angle glaucoma. Current devices were not designed for these patients.
Investor Signal
Preparing for first-in-human evaluation in Singapore. Currently raising seed funding to advance toward clinical-stage development.
Singapore-based company developing first-in-class ophthalmic devices led by a multidisciplinary team combining clinical expertise, engineering innovation, and regulatory strategy.
Preeti Mohan
CEO, Founder
Singapore Biodesign Fellow
Dr. Bert Wouters
CTO, Co-founder
PhD Microfluidic Engineering
Assoc. Prof. Shamira Perera
Clinical Lead, Co-founder
Head of Glaucoma, SNEC
Important Information
Flostream is an investigational medical device. Not approved for commercial use in any jurisdiction. Content on this website is provided for informational purposes only and does not constitute medical advice, promotion, or solicitation.